ArticleMedical oncology (Northwood, London, England)2024
Evidence-based recommendations regarding risk reduction practices for people at risk of or with breast cancer-related lymphedema: consensus from an expert panel.
Article in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The Importance of a Pre-treatment Baseline When Screening Patients for Breast-Cancer-Related Lymphedema.Annals of surgical oncology · 2025Trial
- Preventive effects of progressive resistance training of different intensities on breast cancer-related lymphedema.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Obese Patients Undergoing Implant-based Breast Reconstruction: A Propensity Score-Matched Analysis.Plastic and reconstructive surgery. Global open · 2026Article
- Baseline and early postoperative bioimpedance spectroscopy and perometry measurements in patients treated for breast cancer: insights from a prospective screening program.Breast cancer research and treatment · 2026Article
- Investigation of the current status of lymphedema management in 45 hospitals in China.Gland surgery · 2026Article
- Development and validation of an interpretable stacking-based risk model for breast cancer- related lymphoedema: a cross-sectional study.Frontiers in oncology · 2026Article
- Advancing Lymphedema Surveillance With Evidence-Based Practices.Clinical journal of oncology nursing · 2025Review
- The Effects of Concurrent Training on Molecular, Functional, and Clinical Outcomes in Breast Cancer Survivors: A Pilot Study.Cancers · 2025Article
- Assessing the Impact of Lymphedema Therapy Referral on Breast Cancer Survivors' Lymphedema Knowledge: A Cross-Sectional Survey.BMC women's health · 2025Article
- Lymphovenous anastomosis: microsurgical innovation and clinical outcomes in breast cancer-related lymphedema care.Frontiers in surgery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several recent studies have investigated the validity of precautionary practices for lymphedema risk reduction after breast cancer treatment, such as avoidance of blood pressure measurements, skin puncture, blood draws, and use of prophylactic compression during air travel. Other studies have elucidated risk factors for breast cancer-related lymphedema, such as axillary lymph node dissection and skin infection (cellulitis). Combining the current evidence base with the consensus opinion of lymphatic experts assembled at the American Cancer Society/Lymphology Association of North America Summit in October 2023, updated evidence-based risk reduction recommendations are presented for those with or at risk of breast cancer-related lymphedema. Recommendation topics include prospective surveillance, patient education, individual risk factors, exercise, blood pressure, skin care and hygiene, skin puncture and blood draws, surgical procedures, prophylactic compression, air travel, and hot climate and sauna. These recommendations will help inform education and medical choices for individuals treated for breast cancer who are at risk of or diagnosed with breast cancer-related lymphedema. More high-quality evidence is required to allow the development of risk reduction recommendations for other cancer types such as gynecological, melanoma, and head and neck. It is recommended that clinicians and organizations serving people at risk of or with lymphedema align risk reduction guidelines with the evidence-based recommendations provided within this consensus document and companion manuscripts from the American Cancer Society/Lymphology Association of North America Lymphedema Summit: Forward Momentum: Future Steps in Lymphedema Management.
Indexed as
Identifiers
39438352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.